Supplementary Figure S6 from Unraveling Relatlimab-Specific Biology Using Biomarker Analyses in Patients with Advanced Melanoma in RELATIVITY-047

Key Points

LAG-3 and PD-L1 expression levels were analyzed based on the site of collection, revealing notable variations.
High prevalence rates of LAG-3 and PD-L1 in patients could indicate tailored immunotherapy strategies.
The analysis utilized biomarker assessments to enhance understanding of melanoma treatment response.
Findings may support further investigations into the relationship between biomarker expression and therapy outcomes.

We only have this paper's title and publication details.

Answers are grounded in this paper and cite their sources.

Biomarker analysis shows LAG-3 and PD-L1 expression in advanced melanoma, suggesting relevant treatment insights.

Prevalence of (A) LAG-3 and (B) PD-L1 expression by site of collection.

No takes yet. Share an insight, caveat, or question.

Lipson et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Share